Smoking Termination Opportunity for inPatients (STOP): superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 12-month randomised controlled trial for inpatients. Issue 5 (19th September 2012)

• Record Type: Journal Article
• Authors: Smith, Brian James; Carson, Kristin Veronica; Brinn, Malcolm Philip; Labiszewski, Nadina Ann; Peters, Matthew J; Fitridge, Robert; Koblar, Simon A; Jannes, Jim; Veale, Antony J; Goldsworthy, Sharon J; Litt, John; Edwards, David; Esterman, Adrian Jeffrey
• Is Part Of: Thorax. Volume 68:Issue 5(2013)
• Page Start: 485
• Page End: 486
• Publication Date: 2012-09-19
• Subjects: Tobacco and the lung -- Clinical Epidemiology; Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2012-202484
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Rationale: Smoking cessation interventions in outpatient settings have been demonstrated to be cost effective. Given this evidence, we aimed to evaluate the effectiveness of varenicline tartrate plus Quitline-counselling compared with Quitline-counselling alone when initiated in the inpatient setting. Methods: Adult patients (18–75 years) admitted with a smoking-related illness to three hospitals, were randomised to receive either 12-weeks of varenicline tartrate plus Quitline-counselling, (n=196) or Quitline-counselling alone, (n=196), with 12-months follow-up. Results: For the primary analysis population (intention-to-treat), the proportion of subjects who remained continuously abstinent were significantly greater in the varenicline plus counselling arm (31.1%, n=61) compared with counselling alone (21.4%, n=42; RR 1.45, 95% CI 1.03 to 2.03, p=0.03). Conclusions: The combined use of varenicline plus counselling when initiated in the inpatient setting has produced a sustained smoking cessation benefit at 12-months follow-up, indicating a successful opportunistic treatment for smokers admitted with smoking related illnesses. Trial registration: http://www.clinicaltrials.gov/ ClinicalTrials.gov identification number: NCT01141855 .